Title |
Humoral anti-KLH responses in cancer patients treated with dendritic cell-based immunotherapy are dictated by different vaccination parameters
|
---|---|
Published in |
Cancer Immunology, Immunotherapy, April 2012
|
DOI | 10.1007/s00262-012-1263-z |
Pubmed ID | |
Authors |
Erik H. J. G. Aarntzen, I. Jolanda M. de Vries, Joop H. Göertz, Marjo Beldhuis-Valkis, Huberdina M. L. M. Brouwers, Mandy W. M. M. van de Rakt, Renate G. van der Molen, Cornelis J. A. Punt, Gosse J. Adema, Paul J. Tacken, Irma Joosten, Joannes F. M. Jacobs |
Abstract |
Keyhole limpet hemocyanin (KLH) attracts biomedical interest because of its remarkable immunostimulatory properties. Currently, KLH is used as vaccine adjuvant, carrier protein for haptens and as local treatment for bladder cancer. Since a quantitative human anti-KLH assay is lacking, it has not been possible to monitor the dynamics of KLH-specific antibody (Ab) responses after in vivo KLH exposure. We designed a quantitative assay to measure KLH-specific Abs in humans and retrospectively studied the relation between vaccination parameters and the vaccine-induced anti-KLH Ab responses. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Spain | 1 | 2% |
Unknown | 45 | 98% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 9 | 20% |
Student > Bachelor | 7 | 15% |
Student > Master | 6 | 13% |
Student > Ph. D. Student | 4 | 9% |
Other | 4 | 9% |
Other | 8 | 17% |
Unknown | 8 | 17% |
Readers by discipline | Count | As % |
---|---|---|
Agricultural and Biological Sciences | 11 | 24% |
Medicine and Dentistry | 8 | 17% |
Biochemistry, Genetics and Molecular Biology | 5 | 11% |
Immunology and Microbiology | 5 | 11% |
Pharmacology, Toxicology and Pharmaceutical Science | 3 | 7% |
Other | 6 | 13% |
Unknown | 8 | 17% |